Article Details
Retrieved on: 2024-08-06 00:12:28
Tags for this article:
Click the tags to see associated articles and topics
Summary
The relationship centers on Lepu Biopharma's drug candidate MRG003 receiving Breakthrough Therapy Designation from the FDA for nasopharyngeal carcinoma, highlighting the role of drug development, FDA's regulatory process, and the company's international aspirations within the biopharma sector.
Article found on: www.marketscreener.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here